The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis
Open accessAbstract
Vaccines that drive robust T-cell immunity against Mycobacterium tuberculosis (Mtb) are needed both for prophylactic and therapeutic purposes. We have recently developed a synthetic vaccine delivery platform with Pluronic-stabilized polypropylene sulfide nanoparticles (NPs), which target lymphoid tissues by their small size (∼ 30 nm) and which activate the complement cascade by their surface chemistry. Here we conjugated the tuberculosis antigen Ag85B to the NPs (NP-Ag85B) and compared their efficacy in eliciting relevant immune responses in mice after intradermal or pulmonary administration. Pulmonary administration of NP-Ag85B with the adjuvant CpG led to enhanced induction of antigen-specific polyfunctional Th1 responses in the spleen, the lung and lung-draining lymph nodes as compared to soluble Ag85B with CpG and to the intradermally-delivered formulations. Mucosal and systemic Th17 responses were also observed with this adjuvanted NP formulation and vaccination route, especially in the lung. We then evaluated protection induced by the adjuvanted NP formulation following a Mtb aerosol challenge and found that vaccination with NP-Ag85B and CpG via the pulmonary route displayed a substantial reduction of the lung bacterial burden, both compared to soluble Ag85B with CpG and to the corresponding intradermally delivered formulations. These findings highlight the potential of administrating NP-based formulations by the pulmonary route for TB vaccination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pulmonary administration of the common TB antigen 85B conjugated to poly(propylene sulphide) nanoparticles demonstrated improved protection in mice after they were challenged with aerosolized M. tuberculosis (ref. 135 ).”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [135]
Citations
Cites
Lutz, M. B., Kukutsch, N. A., Ogilvie, A. L. J., Rößner, S., Koch, F., Romani, N., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00204-x · Cited by 2,972
Sample criteria for testing outlying observations
Grubbs, F. E. (1950) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729885 · Cited by 1,631
Khader, S. A., Bell, G. K., Pearl, J. E., Fountain, J. J., Rangel‐Moreno, J., Cilley, G. E., Shen, F., Eaton, S. M., Gaffen, S. L., Swain, S. L., et al. (2007) · Nature Immunology · doi:10.1038/ni1449 · Cited by 1,468
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O’Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,355
Self-citationGlobal tuberculosis control 2010
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,262
Induction and effector functions of TH17 cells
Bettelli, E., Korn, T., Oukka, M., & Kuchroo, V. K. (2008) · Nature · doi:10.1038/nature07036 · Cited by 1,243
The success and failure of BCG — implications for a novel tuberculosis vaccine
Andersen, P. L., & Doherty, T. M. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1211 · Cited by 791
Immune Control of Tuberculosis by IFN-γ-Inducible LRG-47
MacMicking, J. D., Taylor, G. A., & McKinney, J. D. (2003) · Science · doi:10.1126/science.1088063 · Cited by 685
Self-citationMaterials engineering for immunomodulation
Hubbell, J. A., Thomas, S. N., & Swartz, M. A. (2009) · Nature · doi:10.1038/nature08604 · Cited by 581
Self-citationUptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome
Sharp, F. A., Ruane, D., Claass, B., Creagh, E. M., Harris, J., Malyala, P., Singh, M., O’Hagan, D. T., Pétrilli, V., Tschopp, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804897106 · Cited by 536
Cited by
Sorted by citations
From Sewer to Saviour—Targeting the Lymphatic System to Promote Drug Exposure and Activity
Trevaskis, N. L., Kaminskas, L. M., & Porter, C. J. H. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4608 · Cited by 654
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 605
Self-citationNanotechnology approaches for global infectious diseases
Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520
Nanoparticle Vaccines Against Infectious Diseases
Pati, R., Shevtsov, M. A., & Sonawane, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02224 · Cited by 521
Nanoparticle diffusion in respiratory mucus from humans without lung disease
Schuster, B. S., Suk, J. S., Woodworth, G. F., & Hanes, J. S. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.064 · Cited by 478
Metadata
- Authors
- Ballester, M., Nembrini, C., Dhar, N., de Titta, A., de Piano, C., Pasquier, M., Simeoni, E., van der Vlies, A. J., McKinney, J. D., Hubbell, J. A., & Swartz, M. A.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Hubbell, Jeffrey A.
- Swartz, Melody A.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 29
- Issue
- 40
- Pages
- 6959-6966
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W1967877494
- Cited by
- 130
- References
- 33
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 1 · 2021: 9 · 2020: 6 · 2019: 8 · 2018: 13 · 2017: 9 · 2016: 7 · 2015: 7 · 2014: 15 · 2013: 16 · 2012: 10
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- Locations
- Vaccine (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- Bill and Melinda Gates Foundation
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- tuberculosis vaccination, Ag85B, CpG adjuvant, nanoparticle conjugation, Th1 response, Th17 response, Mycobacterium tuberculosis, aerosol challenge, lung bacterial burden, complement activation
- MeSH terms
- Acyltransferases, Animals, Antigens, Bacterial, Bacterial Proteins, Complement System Proteins, Dendritic Cells, Lung, Lymph Nodes, Mice, Inbred C57BL, Mycobacterium tuberculosis, Particle Size, Polypropylenes, Spleen, Tuberculosis, Vaccines, Synthetic, Th1 Cells, Immunoconjugates, CpG Islands, Tuberculosis Vaccines, Mice, Nanoparticles, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
